$72.28
2.123.02%
Last update: Oct 15, 4:00 PM
ANI Pharmaceuticals Inc
ANIPNASDAQ
ANI Pharmaceuticals (ANIP) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ANI Pharmaceuticals (ANIP) last issued guidance on August 7, 2026 for fiscal year 2026. The company guided earnings per share in the range of $9.19 - $9.69, compared to a consensus EPS estimate of $9.1. ANI Pharmaceuticals also guided revenue in the range of $1.08B - $1.14B for the period.
Compared to prior guidance, ANI Pharmaceuticals maintained its EPS outlook from a previous range of $9.19 - $9.69. On the revenue side, the company maintained its revenue forecast from a prior range of $1.08B - $1.14B.
ANI Pharmaceuticals has issued 26 guidance updates between November 9, 2022 and August 7, 2026. During this period, the company raised its outlook 14 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.94 | $1.23 | $1.83 | $1.61 |
| Actual | $2.21 | $2.05 | $2.33 | $2.04 |
| Surprise | +13.9% | +66.7% | +27.3% | +26.7% |
| Revenue | ||||
| Estimate | $263.2M | $207.2M | $231.8M | $212.2M |
| Actual | $266.0M | $237.5M | $247.1M | $227.8M |
| Surprise | +1.08% | +14.6% | +6.58% | +7.34% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.10 | $2.74 | $1.15 | $1.97 |
| Revenue | ||||
| Consensus | $280.2M | $319.0M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 7, 2026 | $2.21 | $1.94 | 13.9 % |
| Q1 | May 8, 2026 | $2.05 | $1.23 | 66.7 % |
| Q4 | Feb 27, 2026 | $2.33 | $1.83 | 27.3 % |
| Q3 | Nov 7, 2025 | $2.04 | $1.61 | 26.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 7, 2026 | $266.04M | $263.20M | 1.08 % |
| Q1 | May 8, 2026 | $237.46M | $207.18M | 14.6 % |
| Q4 | Feb 27, 2026 | $247.06M | $231.81M | 6.58 % |
| Q3 | Nov 7, 2025 | $227.81M | $212.24M | 7.34 % |
